株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

API (原薬) の世界市場 - 2024年までの予測:革新的API、ジェネリックAPI

Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 225648
出版日 ページ情報 英文 255 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
API (原薬) の世界市場 - 2024年までの予測:革新的API、ジェネリックAPI Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024
出版日: 2019年01月07日 ページ情報: 英文 255 Pages
概要

世界のAPI (原薬) 市場は、2019年の1,822億米ドルから、2024年までに2,452億米ドルまで拡大すると見られています。市場は、2019年〜2024年のCAGR (複合年間成長率) で、6.1%の成長が予測されています。

当レポートでは、世界のAPI (原薬) 市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • API:市場概要
  • API市場:種類別
  • API市場:メーカーの種類別
  • API市場:合成の種類別
  • API市場:薬剤の種類別
  • 地域別スナップショット:API市場

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 APIの世界市場:種類別

  • イントロダクション
  • 革新的API
  • ジェネリックAPI

第7章 APIの世界市場:メーカーの種類別

  • イントロダクション
  • キャプティブAPIメーカー
  • マーチャントAPIメーカー

第8章 APIの世界市場:合成の種類別

  • イントロダクション
  • 合成API
  • バイオテクノロジーAPI

第9章 APIの世界市場:薬剤の種類別

  • イントロダクション
  • 処方薬
  • OTC薬
  • API市場:効能別

第10章 APIの世界市場:治療応用別

  • イントロダクション
  • 伝染性疾患
  • 腫瘍
  • 疼痛管理
  • 心血管疾患
  • 糖尿病
  • 呼吸器疾患
  • その他

第11章 APIの世界市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他

第12章 競合情勢

  • 概要
  • 市場企業ランキング
  • 競合リーダーシップマッピング
  • 競合状況と動向

第13章 企業プロファイル

  • PFIZER, INC.
  • NOVARTIS AG
  • SANOFI
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • MERCK & CO., INC.
  • ABBVIE INC.
  • F. HOFFMANN-LA ROCHE
  • ASTRAZENECA

第14章 付録

図表

LIST OF TABLES

  • TABLE 1: INDICATIVE LIST OF DRUGS GOING GENERIC IN 2018
  • TABLE 2: INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN THE US IN 2017-2018
  • TABLE 3: INDICATIVE LIST OF BIOSIMILARS THAT GAINED US REGULATORY APPROVAL IN 2018
  • TABLE 4: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 5: INDICATIVE LIST OF NEW MOLECULAR ENTITIES THAT GAINED US FDA APPROVAL IN 2018
  • TABLE 6: LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2018
  • TABLE 7: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 8: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 9: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 10: CAPTIVE API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 11: LIST OF SIGNIFICANT CMO/CDMO FACILITY EXPANSIONS
  • TABLE 12: MERCHANT API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 13: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 14: MERCHANT INNOVATIVE API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 15: MERCHANT GENERIC API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 16: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 2017-2024 (USD BILLION)
  • TABLE 17: MERCHANT SYNTHETIC API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 18: MERCHANT BIOTECH API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 19: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 20: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 21: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 2017-2024 (USD BILLION)
  • TABLE 22: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 23: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 24: TOP SELLING BIOLOGICS (2018)
  • TABLE 25: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 26: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 27: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 28: INDICATIVE LIST OF BIOSIMILARS THAT GAINED US FDA APPROVAL DURING 2017-2018
  • TABLE 29: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 30: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 2017-2024 (USD BILLION)
  • TABLE 31: INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2018
  • TABLE 32: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 33: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 34: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 35: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 36: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 37: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 38: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 39: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2017-2024 (USD BILLION)
  • TABLE 40: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 41: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 42: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 43: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 44: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 46: PRESCRIPTION DRUGS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 47: OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 48: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 49: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 50: INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR COMMUNICABLE DISEASES (2018)
  • TABLE 51: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 52: INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR ONCOLOGY (2018)
  • TABLE 53: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 54: INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR PAIN MANAGEMENT (2018)
  • TABLE 55: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 56: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 57: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 58: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 59: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 60: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 61: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 62: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 63: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 64: NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 65: NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 66: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 67: NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 68: NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 69: NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017-2024 (USD BILLION)
  • TABLE 70: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 71: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 72: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 73: INDICATIVE LIST OF RECENT FDA APPROVALS FOR DRUG DELIVERY PRODUCTS
  • TABLE 74: US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 75: US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 76: US: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 77: US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 78: US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 79: US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 80: US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 81: US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 82: US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 83: US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 84: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 85: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 86: CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 87: CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 88: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 89: CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 90: CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 91: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 92: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 93: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 94: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 95: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 96: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 97: EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 98: EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 99: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 100: EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 101: EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 102: EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017-2024 (USD BILLION)
  • TABLE 103: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 104: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 105: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 106: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 107: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 108: GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 109: GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 110: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 111: GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 112: GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 113: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 114: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 115: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 116: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 117: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 118: FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 119: FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 120: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 121: FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 122: FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 123: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 124: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 125: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 126: UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 127: UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 128: UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 129: UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 130: UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 131: UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 132: UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 133: UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 134: UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 135: UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 136: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 137: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 138: ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 139: ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 140: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 141: ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 142: ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 143: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 144: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 145: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 146: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 147: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 148: SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 149: SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 150: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 151: SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 152: SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 153: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 154: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD MILLION)
  • TABLE 155: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 156: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 157: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 158: ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 159: ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 160: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 161: ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 162: ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 163: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 164: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 165: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 166: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 167: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 168: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 169: ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 170: ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 171: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 172: ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 173: ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 174: ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 175: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 176: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 177: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 178: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 179: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 180: JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 181: JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 182: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 183: JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 184: JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 185: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 186: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 187: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 188: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 189: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 190: CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 191: CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 192: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 193: CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 194: CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 195: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 196: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 197: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 198: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 199: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 200: INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 201: INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 202: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 203: INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 204: INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 205: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 206: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 207: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 208: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 209: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 210: SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 211: SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 212: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 213: SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 214: SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 215: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 216: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 217: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 218: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 219: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 220: ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 221: ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 222: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 223: ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 224: ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 225: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 226: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 227: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 228: ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 229: ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 230: ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 231: ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 232: ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 233: ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 234: ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 235: ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 236: ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 237: ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 238: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2018
  • TABLE 239: PRODUCT LAUNCHES, 2016-2018
  • TABLE 240: EXPANSIONS, 2016-2018
  • TABLE 241: ACQUISITIONS, 2015-2018
  • TABLE 242: OTHER STRATEGIES, 2015-2018
  • TABLE 243: EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF EUR TO USD)
  • TABLE 244: EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD)
  • TABLE 245: EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF CHF TO USD)

LIST OF FIGURES

  • FIGURE 1: APIS: MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
  • FIGURE 8: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2019 VS. 2024
  • FIGURE 9: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2019 VS. 2024
  • FIGURE 10: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2019 VS. 2024
  • FIGURE 11: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2019 VS. 2024
  • FIGURE 12: GEOGRAPHICAL SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • FIGURE 13: INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS ARE DRIVING MARKET GROWTH
  • FIGURE 14: GENERIC APIS TO GROW AT THE HIGHEST CAGR FROM 2019 TO 2024
  • FIGURE 15: MERCHANT API MANUFACTURERS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 16: ONCOLOGY SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17: PRESCRIPTION DRUGS TO COMMAND THE LARGEST MARKET SHARE IN 2019
  • FIGURE 18: CHINA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 19: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT TO DOMINATE THE MARKET IN 2019
  • FIGURE 21: CAPTIVE MANUFACTURERS SEGMENT TO DOMINATE THE MARKET IN 2019
  • FIGURE 22: SYNTHETIC APIS TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 23: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG
  • FIGURE 24: LOW-TO-MODERATE SEGMENT TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, IN 2019
  • FIGURE 25: COMMUNICABLE DISEASES TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN 2019
  • FIGURE 26: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 27: EUROPE: MARKET SNAPSHOT
  • FIGURE 28: EXPANSIONS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO OCTOBER 2018
  • FIGURE 29: COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - OVERALL MARKET
  • FIGURE 30: COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - START-UP/SME
  • FIGURE 31: PFIZER, INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 32: NOVARTIS AG: COMPANY SNAPSHOT (2017)
  • FIGURE 33: SANOFI: COMPANY SNAPSHOT (2017)
  • FIGURE 34: BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017)
  • FIGURE 35: BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2017)
  • FIGURE 36: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2017)
  • FIGURE 37: ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2017)
  • FIGURE 38: GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2017)
  • FIGURE 39: MERCK & CO., INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 40: ABBVIE INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 41: F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2017)
  • FIGURE 42: ASTRAZENECA: COMPANY SNAPSHOT (2017)
目次
Product Code: PH 1262

"Increasing incidence of chronic diseases and technological advancements in API manufacturing are expected to drive the overall growth of the global APIs market."

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.

On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in demand for monoclonal antibodies, and their similarity with the natural biological compounds found in the human body influence the growth of this segment.

The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market.

Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the biotech APIs market. Factors such as the increasing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and reduced side effects as compared to chemotherapy are responsible for driving this market.

North America to dominate the market during the forecast period.

In 2019, North America is expected to dominate the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 37%, Tier 2: 22%, Tier 3: 41%
  • By Designation - C-level: 25%, D-level: 20%, Others: 55%
  • By Region - North America: 40%, Europe: 27%, Asia: 20%, RoW: 13%

List of Companies Profiled in the Report:

  • Pfizer, Inc. (US)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb (US)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (US)
  • GlaxoSmithKline plc (UK)
  • Merck & Co., Inc. (US)
  • AbbVie Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AstraZeneca plc (UK)

Research Coverage:

This report provides a picture of the global APIs market. It aims at estimating the size and future growth potential of the market across different segments, such as type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them the closest approximations of the revenue numbers for the overall APIs market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY SOURCES
      • 2.1.1.1 Key Data from Secondary Sources
    • 2.1.2 PRIMARY SOURCES
      • 2.1.2.1 Key Data from Primary Sources
      • 2.1.2.2 Key Industry Insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW
  • 4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
  • 4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
  • 4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS
  • 4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG
  • 4.6 GEOGRAPHIC SNAPSHOT: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of chronic diseases
      • 5.2.1.2 Technological advancements in API manufacturing
      • 5.2.1.3 Growing importance of generics
      • 5.2.1.4 Increasing uptake of biopharmaceuticals
      • 5.2.1.5 Growing adoption of artificial intelligence-based tools for drug discovery
      • 5.2.1.6 Adoption of organ-on-chip models in drug development
      • 5.2.1.7 Growing focus on precision medicine
      • 5.2.1.8 Growing investments in real-world evidence by pharmaceutical companies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable drug price control policies across various countries
      • 5.2.2.2 Increasing penetration of counterfeit drugs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging biosimilars market
      • 5.2.3.2 Highly potent active pharmaceutical ingredients
      • 5.2.3.3 Emerging markets
      • 5.2.3.4 Emerging technologies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Product differentiation - A major concern for API manufacturers
      • 5.2.4.2 High manufacturing costs

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVAL TO DRIVE MARKET GROWTH
  • 6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER

  • 7.1 INTRODUCTION
  • 7.2 CAPTIVE API MANUFACTURERS
    • 7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY HAVE DRIVEN FOCUS ON CAPTIVE MANUFACTURING
  • 7.3 MERCHANT API MANUFACTURERS
    • 7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE
      • 7.3.1.1 Merchant Innovative API Manufacturers
        • 7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain market growth
      • 7.3.1.2 Merchant Generic API Manufacturers
        • 7.3.1.2.1 Low manufacturing cost of generics likely to drive the growth of this segment

    • 7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
      • 7.3.2.1 Merchant Synthetic API Manufacturers
        • 7.3.2.1.1 Need for specialized manufacturing capabilities has resulted in expansion among market players in this segment
      • 7.3.2.2 Merchant Biotech API Manufacturers
        • 7.3.2.2.1 Complexity of manufacturing biotech APIs has driven focus on partnerships between companies and CMOs

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS

  • 8.1 INTRODUCTION
  • 8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • 8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
      • 8.2.1.1 Innovative synthetic APIs
        • 8.2.1.1.1 The high value of innovative APIs to drive the growth of this segment
      • 8.2.1.2 Generic synthetic APIs
        • 8.2.1.2.1 Initiatives to promote the penetration of generics to bring down healthcare costs-a major growth driver
  • 8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
    • 8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
      • 8.3.1.1 Innovative biotech APIs
        • 8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the market for this segment
      • 8.3.1.2 Generic biotech APIs
        • 8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment
    • 8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
      • 8.3.2.1 Monoclonal antibodies
        • 8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment
      • 8.3.2.2 Hormones & growth factors
        • 8.3.2.2.1 The growing incidence of hormonal disorders to drive the market for this segment
      • 8.3.2.3 Cytokines
        • 8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment
      • 8.3.2.4 Fusion proteins
        • 8.3.2.4.1 Growing applications of Fc fusion proteins in biopharmaceuticals to drive the growth of this segment
      • 8.3.2.5 Recombinant vaccines
        • 8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development-a positive indicator of growth
      • 8.3.2.6 Therapeutic enzymes
        • 8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive the growth of this segment
      • 8.3.2.7 Blood factors
        • 8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment
    • 8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM
      • 8.3.3.1 Mammalian expression systems
        • 8.3.3.1.1 Ability of these systems to carry post-translational modification to drive the market for this segment
      • 8.3.3.2 Microbial expression systems
        • 8.3.3.2.1 Ability of these expression systems to provide high expression levels of proteins to drive the market for this segment
      • 8.3.3.3 Yeast expression systems
        • 8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand
      • 8.3.3.4 Insect expression systems
        • 8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand
      • 8.3.3.5 Other expression systems

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG

  • 9.1 INTRODUCTION
  • 9.2 PRESCRIPTION DRUGS
    • 9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET
  • 9.3 OVER-THE-COUNTER DRUGS
    • 9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS
  • 9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY
    • 9.4.1 LOW-TO-MODERATE POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
    • 9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 COMMUNICABLE DISEASES
    • 10.2.1 GLOBAL HEALTH IMPACT OF COMMUNICABLE DISEASES AND INCREASING ANTIMICROBIAL RESISTANCE-KEY MARKET DRIVERS
  • 10.3 ONCOLOGY
    • 10.3.1 INCREASE IN GLOBAL SPENDING ON CANCER MEDICATION TO BOOST THE MARKET FOR THIS SEGMENT
  • 10.4 PAIN MANAGEMENT
    • 10.4.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET

  • 10.5 CARDIOVASCULAR DISEASES
    • 10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER
  • 10.6 DIABETES
    • 10.6.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT
  • 10.7 RESPIRATORY DISEASES
    • 10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT
  • 10.8 OTHER THERAPEUTIC APPLICATIONS

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 US
      • 11.2.1.1 Increasing expenditure on medicine is expected to drive the APIs market in the US
    • 11.2.2 CANADA
      • 11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada
  • 11.3 EUROPE
    • 11.3.1 GERMANY
      • 11.3.1.1 Germany to dominate the market in Europe
    • 11.3.2 FRANCE
      • 11.3.2.1 Emergence of pharmerging markets in Asia may hinder market growth in France
    • 11.3.3 UK
      • 11.3.3.1 Growing adoption of generics will drive the growth of the UK market
    • 11.3.4 ITALY
      • 11.3.4.1 Italy's share in the global merchant APIs market is expected to remain stable over the forecast period
    • 11.3.5 SPAIN
      • 11.3.5.1 Spanish market has been typically dominated by branded drugs
    • 11.3.6 REST OF EUROPE
  • 11.4 ASIA
    • 11.4.1 JAPAN
      • 11.4.1.1 Japanese government aims to boost the use of generics by 2020
    • 11.4.2 CHINA
      • 11.4.2.1 Government policies to increase medicine access and affordability will support market growth
    • 11.4.3 INDIA
      • 11.4.3.1 India is a leading producer of generics

    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Government initiatives to introduce full medical coverage for major chronic diseases likely to drive this market
    • 11.4.5 REST OF ASIA
  • 11.5 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 MARKET PLAYER RANKING
  • 12.3 COMPETITIVE LEADERSHIP MAPPING - OVERALL MARKET
    • 12.3.1 VANGUARDS
    • 12.3.2 DYNAMIC DIFFERENTIATORS
    • 12.3.3 INNOVATORS
    • 12.3.4 EMERGING PLAYERS
  • 12.4 COMPETITIVE LEADERSHIP MAPPING - START-UP/SME
    • 12.4.1 PROGRESSIVE COMPANIES
    • 12.4.2 STARTING BLOCKS
    • 12.4.3 RESPONSIVE COMPANIES
    • 12.4.4 DYNAMIC COMPANIES
  • 12.5 COMPETITIVE SITUATION AND TRENDS
    • 12.5.1 PRODUCT LAUNCHES
    • 12.5.2 EXPANSIONS
    • 12.5.3 ACQUISITIONS
    • 12.5.4 OTHER STRATEGIES

13 COMPANY PROFILES

(Business overview, Products offered, Recent Developments, MNM view)*

  • 13.1 PFIZER, INC.
  • 13.2 NOVARTIS AG
  • 13.3 SANOFI
  • 13.4 BOEHRINGER INGELHEIM
  • 13.5 BRISTOL-MYERS SQUIBB
  • 13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 13.7 ELI LILLY AND COMPANY
  • 13.8 GLAXOSMITHKLINE PLC
  • 13.9 MERCK & CO., INC.
  • 13.10 ABBVIE INC.
  • 13.11 F. HOFFMANN-LA ROCHE
  • 13.12 ASTRAZENECA

Details on Business overview, Products offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Back to Top